In last trading session, Eliem Therapeutics Inc (NASDAQ:ELYM) saw 0.59 million shares changing hands with its beta currently measuring -0.37. Company’s recent per share price level of $4.98 trading at -$0.02 or -0.40% at ring of the bell on the day assigns it a market valuation of $333.96M. That closing price of ELYM’s stock is at a discount of -131.93% from its 52-week high price of $11.55 and is indicating a premium of 52.81% from its 52-week low price of $2.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.59 million shares which gives us an average trading volume of 472.80K if we extend that period to 3-months.
For Eliem Therapeutics Inc (ELYM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eliem Therapeutics Inc (NASDAQ:ELYM) trade information
Upright in the red during last session for losing -0.40%, in the last five days ELYM remained trading in the red while hitting it’s week-highest on Monday, 09/23/24 when the stock touched $4.98 price level, adding 41.96% to its value on the day. Eliem Therapeutics Inc’s shares saw a change of 84.44% in year-to-date performance and have moved -40.93% in past 5-day. Eliem Therapeutics Inc (NASDAQ:ELYM) showed a performance of -19.68% in past 30-days. Number of shares sold short was 1.15 million shares which calculate 4.07 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.72% during past 5 years.
Eliem Therapeutics Inc (NASDAQ:ELYM)’s Major holders
Insiders are in possession of 10.38% of company’s total shares while institution are holding 77.67 percent of that, with stock having share float percentage of 86.67%. Investors also watch the number of corporate investors in a company very closely, which is 77.67% institutions for Eliem Therapeutics Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at ELYM for having 31.42 million shares of worth $223.39 million. And as of 2024-06-30, it was holding 103.5246 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 3.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.866 of outstanding shares, having a total worth of $27.76 million.
